Merck's eye drug met the vision benchmark, but eye complications were more frequent

Merck's eye drug met the vision benchmark, but eye complications were more frequent  Stock Titan

Summary aggregated from Stock Titan's public RSS feed. The full reporting belongs to Stock Titan — please read it on their site.